MediciNova, Inc. (MNOV)
MNOV moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How MNOV actually reacts to news — the realized, point-in-time move the market made, measured across 117 labeled events over the last three years with zero look-ahead.
MNOV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 27% | 108 |
| 30-min | 0.00% | 43% | 115 |
| 60-min | 0.00% | 48% | 115 |
| to close | 0.00% | 40% | 116 |
| Middle 50% of MNOV reactions | -1.36% to +1.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 117 |
Half of all MediciNova, Inc. news events land between -1.36% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MNOV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 82 | 0.00% | 35% | 0.00% |
| Rating reiterations | 27 | 0.00% | 44% | +0.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MNOV ranks against every other measured name →
That’s how MNOV usually reacts — get an email when it moves on news →Email me when MNOV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MNOV's baseline. Nothing else.
Recent MNOV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MediciNova CEO Provides Shareholder Update | Press release | GlobeNewswire | +2.01% | +3.36% | |
| MediciNova to Participate in the Maxim Growth Summit | Press release | GlobeNewswire | -0.12% | -4.07% | |
| Form 8-K MEDICINOVA INC For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -7.07% | -6.34% | |
| MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | Press release | GlobeNewswire | -2.94% | -14.29% | |
| MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) | Press release | GlobeNewswire | -7.11% | -0.75% | |
| MediciNova to Participate in Two Investor Conferences in September | Press release | GlobeNewswire | +0.90% | +4.79% | |
| Form 8-K MEDICINOVA INC For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | — | -0.69% | |
| Form 8-K MEDICINOVA INC For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +2.22% | |
| Form 10-Q MEDICINOVA INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.76% | -0.76% | |
| MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients | Press release | GlobeNewswire | +1.11% | +3.70% | |
| MediciNova CEO Provides Shareholder Update | Press release | GlobeNewswire | +0.00% | +2.33% | |
| Form 8-K MEDICINOVA INC For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.24% | |
| MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment | Press release | GlobeNewswire | -2.22% | -3.70% | |
| MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | Press release | GlobeNewswire | -2.12% | -3.62% | |
| Form 10-Q MEDICINOVA INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.72% | |
| Form ARS MEDICINOVA INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.46% | |
| Form DEF 14A MEDICINOVA INC For: Jun 23 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.46% | |
| Form DEFA14A MEDICINOVA INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.46% | |
| New Peer-Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation | Press release | GlobeNewswire | — | -0.73% | |
| Form PRER14A MEDICINOVA INC | SEC filing · Form PRER14A | SEC EDGAR | -1.33% | -5.33% | |
| Form PRE 14A MEDICINOVA INC For: Jun 23 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.69% | |
| MediciNova to Participate at the 38th Annual ROTH Conference | Press release | GlobeNewswire | -1.37% | -0.69% | |
| Form 10-K MEDICINOVA INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.40% | -0.70% | |
| Form 8-K MEDICINOVA INC For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.66% | |
| MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients | Press release | GlobeNewswire | -1.09% | -6.01% | |
| 2026 New Year’s Greetings from the CEO | Press release | GlobeNewswire | +0.00% | -2.13% | |
| Form 8-K MEDICINOVA INC For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +6.40% | +3.20% | |
| MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy | Press release | GlobeNewswire | +1.34% | -2.69% | |
| Form EFFECT MEDICINOVA INC | SEC filing · Form EFFECT | SEC EDGAR | -0.64% | +3.36% | |
| MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND | Press release | GlobeNewswire | -1.56% | -4.43% | |
| Form S-3 MEDICINOVA INC | SEC filing · Form S-3 | SEC EDGAR | -1.56% | -4.43% | |
| Message from the CEO to MediciNova Shareholders | Press release | GlobeNewswire | +2.10% | +2.80% | |
| MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor | Press release | GlobeNewswire | +0.69% | +0.00% | |
| Form 10-Q MEDICINOVA INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.65% | — | |
| MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards | Press release | GlobeNewswire | +0.00% | -3.40% | |
| MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | Press release | GlobeNewswire | +1.05% | -0.70% | |
| MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication | Press release | GlobeNewswire | -0.73% | +22.06% | |
| MediciNova to Present at the LD Micro Main Event XIX Investor Conference | Press release | GlobeNewswire | +1.34% | +0.00% | |
| Form EFFECT MEDICINOVA INC | SEC filing · Form EFFECT | SEC EDGAR | -1.57% | -1.57% | |
| MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) | Press release | GlobeNewswire | +0.00% | +0.79% | |
| MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND | Press release | GlobeNewswire | +0.00% | +2.46% | |
| MediciNova Provides Shareholder Update on Key Developments | Press release | GlobeNewswire | +0.00% | -3.82% | |
| MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +0.76% | |
| MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial | Press release | GlobeNewswire | -2.09% | -6.29% | |
| Form S-1 MEDICINOVA INC | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -1.49% | |
| Form 10-Q MEDICINOVA INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.56% | +2.34% | |
| Form 8-K MEDICINOVA INC For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -10.00% | -4.67% | |
| MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million | Press release | GlobeNewswire | -10.00% | -4.67% | |
| MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials | Press release | GlobeNewswire | +0.00% | -0.80% | |
| Form 8-K MEDICINOVA INC For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MNOV section they belong to.
Where else MNOV is measured.
MNOV earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ChromaDex Corporation (CDXC) | 118 | +0.80% | 61% |
| ADHERA THERAPEUTICS INC (ATRX) | 117 | 0.00% | 23% |
| SPROUTLY CDA INC (SRUTF) | 117 | 0.00% | 45% |
| Cannabis Sativa, Inc. (CBDS) | 114 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MediciNova, Inc.'s median reaction calculated?
Every labeled MNOV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 117 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of MNOV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MNOV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.